On March 2, 2020, CRISPR's stock opened at a price of $54. By January 2021, amid the meme stock hype, shares of CRISPR reached highs of more than $200, and the stock was looking like a fantastic buy.

Analysts aren't deterred though, including Citi 's Yigal Nochomovitz, who recently raised his price target on CRSPR from $82 to $88 per share on growing demand for the aforementioned Casgevy. That's ...

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

Drug-resistant tuberculosis remains one of the most stubborn obstacles in global infectious disease control, and a new mini ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Rockville, March 15, 2023 (GLOBE NEWSWIRE) -- Fact.MR – A Market research and competitive intelligence provider: The global CRISPR and Cas genes market expanded market size at a CAGR of 20% during the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

This week marks an incredible win for modern medicine. The first CRISPR-based gene therapy has just been approved for clinical use in the United Kingdom. Casegvy (Exa-cel), developed by Vertex and ...